Monograph
A02BA53 - Famotidine, Combinations |
Propably not porphyrinogenic |
PNP |
Rationale
Famotidine: Partly unmetabolized. No clinical observations pointing to CYP inducing properties. Combined with two inorganic salts without CYP intarective properties
Chemical description
Famotidine: Used in ventricular hyperacidity (H2-receptor antagonist). About 70% excreted in urine in unmetabolized form. Partly metabolized in the liver to inactive sulfoxide metabolite. Impaired liver function does not seem to change the kinetics. Famotidine: South African list: use with care. French list: avoid
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Norway
Poland
Finland© NAPOS 2024